Our key topics

We are committed to ensuring that all patients in Switzerland receive the best possible medicines and therapies as quickly as possible through their basic insurance. This requires rapid approval by Swissmedic, reimbursement through basic insurance from the date of approval, and sustainable models for rewarding innovation. We guarantee the highest possible quality of these medicines and therapies. And we do our part to ensure that the costs of these therapies remain in reasonable proportion to the benefits for patients, society and the economy.

Switzerland and the pharmaceutical industry have been on a successful path together for decades: attractive economic conditions have fostered the impressive development of the research-based pharmaceutical industry. At the same time, the pharmaceutical sector, as a pillar of the economy, contributes disproportionately to Switzerland’s prosperity. The pharmaceutical industry will continue to need optimal conditions in the future, and Switzerland needs successful companies. Political stability, legal certainty, open export markets, the availability of skilled labour and an attractive fiscal environment play an essential role in this symbiosis.

In Switzerland, we now live longer and better lives because the population benefits from innovative medicines and has access to high-quality healthcare. However, there is a need for action and improvement in various areas, and there are new challenges that urgently require solutions. These include, for example, promoting a globally leading ecosystem for health data, flexible remuneration models for innovation, and intensified cooperation with authorities.